Cargando…

Prognostic and predictive value of radiomic signature in stage I lung adenocarcinomas following complete lobectomy

BACKGROUND: The overall survival (OS) of stage I operable lung cancer is relatively low, and not all patients can benefit from adjuvant chemotherapy. This study aimed to develop and validate a radiomic signature (RS) for prediction of OS and adjuvant chemotherapy candidates in stage I lung adenocarc...

Descripción completa

Detalles Bibliográficos
Autores principales: Nie, Wei, Tao, Guangyu, Lu, Zhenghai, Qian, Jie, Ge, Yaqiong, Wang, Shuyuan, Zhang, Xueyan, Zhong, Hua, Yu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331779/
https://www.ncbi.nlm.nih.gov/pubmed/35902907
http://dx.doi.org/10.1186/s12967-022-03547-9
_version_ 1784758485246803968
author Nie, Wei
Tao, Guangyu
Lu, Zhenghai
Qian, Jie
Ge, Yaqiong
Wang, Shuyuan
Zhang, Xueyan
Zhong, Hua
Yu, Hong
author_facet Nie, Wei
Tao, Guangyu
Lu, Zhenghai
Qian, Jie
Ge, Yaqiong
Wang, Shuyuan
Zhang, Xueyan
Zhong, Hua
Yu, Hong
author_sort Nie, Wei
collection PubMed
description BACKGROUND: The overall survival (OS) of stage I operable lung cancer is relatively low, and not all patients can benefit from adjuvant chemotherapy. This study aimed to develop and validate a radiomic signature (RS) for prediction of OS and adjuvant chemotherapy candidates in stage I lung adenocarcinoma. METHODS: A total of 474 patients from 2 centers were divided into 1 training (n = 287), 1 internal validation (n = 122), and 1 external validation (n = 65) cohorts. We extracted 1218 radiomic features from preoperative CT images and constructed RS. We further investigated the prognostic value of the RS in survival analysis. Interaction between treatment and RS was assessed to evaluate its predictive value. Propensity score matching (PSM) was conducted. RESULTS: Overall, 474 eligible patients with stage I lung adenocarcinoma (214 men [45.1%]; median age, 60 years) were identified. The RS was significantly associated with OS in the training and two validation cohorts (hazard ratios [HRs]  >  = 3.22). In multivariable analysis, the RS remained an independent prognostic factor adjusting for clinicopathologic variables (adjusted HRs >  = 2.63). The prognostic value of RS was also confirmed in PSM analysis. In stage I patients, the interaction between RS status and adjuvant chemotherapy was significant (interaction P = 0.020). Within the stratified analysis, good chemotherapy efficacy was only observed for patients with stage IB disease (interaction P < 0.001). CONCLUSIONS: Our results suggested that the radiomic signature was associated with overall survival in patients with stage I lung adenocarcinoma and might predict adjuvant chemotherapy benefit, especially in stage IB patients. The potential of radiomic signature as a noninvasive predictor needed to be confirmed in future studies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03547-9.
format Online
Article
Text
id pubmed-9331779
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93317792022-07-29 Prognostic and predictive value of radiomic signature in stage I lung adenocarcinomas following complete lobectomy Nie, Wei Tao, Guangyu Lu, Zhenghai Qian, Jie Ge, Yaqiong Wang, Shuyuan Zhang, Xueyan Zhong, Hua Yu, Hong J Transl Med Research BACKGROUND: The overall survival (OS) of stage I operable lung cancer is relatively low, and not all patients can benefit from adjuvant chemotherapy. This study aimed to develop and validate a radiomic signature (RS) for prediction of OS and adjuvant chemotherapy candidates in stage I lung adenocarcinoma. METHODS: A total of 474 patients from 2 centers were divided into 1 training (n = 287), 1 internal validation (n = 122), and 1 external validation (n = 65) cohorts. We extracted 1218 radiomic features from preoperative CT images and constructed RS. We further investigated the prognostic value of the RS in survival analysis. Interaction between treatment and RS was assessed to evaluate its predictive value. Propensity score matching (PSM) was conducted. RESULTS: Overall, 474 eligible patients with stage I lung adenocarcinoma (214 men [45.1%]; median age, 60 years) were identified. The RS was significantly associated with OS in the training and two validation cohorts (hazard ratios [HRs]  >  = 3.22). In multivariable analysis, the RS remained an independent prognostic factor adjusting for clinicopathologic variables (adjusted HRs >  = 2.63). The prognostic value of RS was also confirmed in PSM analysis. In stage I patients, the interaction between RS status and adjuvant chemotherapy was significant (interaction P = 0.020). Within the stratified analysis, good chemotherapy efficacy was only observed for patients with stage IB disease (interaction P < 0.001). CONCLUSIONS: Our results suggested that the radiomic signature was associated with overall survival in patients with stage I lung adenocarcinoma and might predict adjuvant chemotherapy benefit, especially in stage IB patients. The potential of radiomic signature as a noninvasive predictor needed to be confirmed in future studies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03547-9. BioMed Central 2022-07-28 /pmc/articles/PMC9331779/ /pubmed/35902907 http://dx.doi.org/10.1186/s12967-022-03547-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Nie, Wei
Tao, Guangyu
Lu, Zhenghai
Qian, Jie
Ge, Yaqiong
Wang, Shuyuan
Zhang, Xueyan
Zhong, Hua
Yu, Hong
Prognostic and predictive value of radiomic signature in stage I lung adenocarcinomas following complete lobectomy
title Prognostic and predictive value of radiomic signature in stage I lung adenocarcinomas following complete lobectomy
title_full Prognostic and predictive value of radiomic signature in stage I lung adenocarcinomas following complete lobectomy
title_fullStr Prognostic and predictive value of radiomic signature in stage I lung adenocarcinomas following complete lobectomy
title_full_unstemmed Prognostic and predictive value of radiomic signature in stage I lung adenocarcinomas following complete lobectomy
title_short Prognostic and predictive value of radiomic signature in stage I lung adenocarcinomas following complete lobectomy
title_sort prognostic and predictive value of radiomic signature in stage i lung adenocarcinomas following complete lobectomy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331779/
https://www.ncbi.nlm.nih.gov/pubmed/35902907
http://dx.doi.org/10.1186/s12967-022-03547-9
work_keys_str_mv AT niewei prognosticandpredictivevalueofradiomicsignatureinstageilungadenocarcinomasfollowingcompletelobectomy
AT taoguangyu prognosticandpredictivevalueofradiomicsignatureinstageilungadenocarcinomasfollowingcompletelobectomy
AT luzhenghai prognosticandpredictivevalueofradiomicsignatureinstageilungadenocarcinomasfollowingcompletelobectomy
AT qianjie prognosticandpredictivevalueofradiomicsignatureinstageilungadenocarcinomasfollowingcompletelobectomy
AT geyaqiong prognosticandpredictivevalueofradiomicsignatureinstageilungadenocarcinomasfollowingcompletelobectomy
AT wangshuyuan prognosticandpredictivevalueofradiomicsignatureinstageilungadenocarcinomasfollowingcompletelobectomy
AT zhangxueyan prognosticandpredictivevalueofradiomicsignatureinstageilungadenocarcinomasfollowingcompletelobectomy
AT zhonghua prognosticandpredictivevalueofradiomicsignatureinstageilungadenocarcinomasfollowingcompletelobectomy
AT yuhong prognosticandpredictivevalueofradiomicsignatureinstageilungadenocarcinomasfollowingcompletelobectomy